Proven Indication, Novel Combination Immunicum has identified the opportunity for the advancement of ilixadencel in kidney cancer to test our lead candidate in a triple combination - specifically, | …

Dec 8, 2020 Ilixadencel tested in the ongoing multi-indication Phase Ib/II ILIAD study of breakthrough combination with ilixadencel and CTLA4 in RCC

A phase 2 clinical trial with a new treatment called ilixadencel in combination with sunitinib has shown to improve overall survival in newly diagnosed patients with metastatic renal cell carcinoma (RCC). People given the combination treatment lived 10 months longer than those on sunitinib alone, suggesting that ilixadencel aids survival in these patients. Ilixadencel is … Immunicum has completed enrolling patients for its ongoing Phase II Metastatic REnal Cell Carcinoma (MERECA) clinical trial of Ilixadencel for the treatment of renal cell cancer (RCC). A total of 88 patients have been randomised in the trial to meet requirements of the study design and validity of the protocol. Ilixadencel is an off-the-shelf cancer immune primer developed for the treatment of solid tumors. The MERECA clinical trial evaluated the therapeutic impact of combining ilixadencel with sunitinib in advanced kidney cancer. For the study, 88 newly-diagnosed, intermediate- and poor-prognosis patients with metastatic RCC were enrolled.

Ilixadencel rcc

2 weeks control – no ilixadencel injections. Jan 27, 2021 Ilixadencel Gets Orphan Drug Designation for Soft Tissue Sarcoma was conducted in patients with metastatic renal cell carcinoma (RCC). Sep 10, 2019 A combination therapy of ilixadencel plus sunitinib (Sutent) achieved complete tumor responses in patients with metastatic renal cell carcinoma Aug 26, 2020 The combination of the off-the-shelf cancer immune primer Ilixadencel and sunitinib has demonstrated promising survival benefit when used as Jun 20, 2017 At the time of inclusion, all 12 patients were assessed as RCC with at by ELISpot at baseline and 2 weeks after the second ilixadencel dose. To-date ilixadencel has been tested in a range of clinical trials in various solid tumor indications including metastatic Renal Cell Carcinoma (mRCC), May 4, 2015 Condition or disease, Intervention/treatment, Phase.

Vidare beviljade amerikanska FDA särläkemedelsstatus (Orphan Drug Designation) för ilixadencel in hepatocellular carcinoma (HCC).

Ilixadencel: unique off-the-shelf cell therapy that kick-starts immune response. Phase 2 Phase 1/2 RCC: intratumoral injection in kidney of metastatic patients

The regulatory decision was based on prior data from The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib (Sutent) trended toward a benefit in overall survival (OS) compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma (RCC), according to updated results of the phase II MERECA trial (NCT02432846) presented during the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium. 1,2 The FDA has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to ilixadencel, as treatment of metastatic renal cell carcinoma (RCC), Immunicum AB announced in a press release. 1. “We are very excited to have received the RMAT designation for ilixadencel in kidney cancer as it recognizes both the potential of our novel therapeutic Ilixadencel did not add any clinically meaningful treatment-related grade 3-4 adverse events or serious adverse events, Dr. Lindskog said.

Njurcancer (RCC) - beprövad indikation, ny kombination Baserat på de nyligen förändrade riktlinjerna kring standardbehandling och våra lovande prekliniska data kring ilixadencel i kombination med anti-PD1 och anti-CTLA4, har vi beslutat att addera ilixadencel till etablerad kombinationsbehandling med anti-CTLA-4 (ipilimumab)

#wewontrest #cancer #CAR-T @BCF_1982 #RCC #Nätverket mot cancer Se och läs Immunicums Ilixadencel blir skräddarsytt i patientens Immunicums ledande produkt ilixadencel utnyttjar den unika och kritiska mation om de pågående studierna inom RCC och GIST, se avsnittet De prekliniska resultaten visar hur ilixadencel genererar komplementära immunologiska Njurcancer (RCC) Rekryteringen har slutförts till den pågående Ilixadencel är en off-the shelf - produkt framtagen från friska allogena Fas II Fas III Ilixadencel IM-201 Njure (RCC) Ilixadencel IM-102 Lever (HCC) Ilixadencel Cancercentrum (RCC). Du kan också I studierna hittills har ilixadencels säkerhetsprofil olika cancerformer där ilixadencel skulle kunna Bernie Maddog har fått RCC, Immunicum AB, 20-02-06 12:32 Detta pga alla nya potentiella behandlingar så det är orimligt att Ilixadencel når Fas II delen av ILIAD, där man utvärderar effekt av ilixadencel i med BMS nivolumab + ipilimumab i RCC innan man tar ställning till fas III. Bolaget har även en pågående fas II-studie inom njurcancer (RCC) kallad Det intressantaste med verkningsmekanismen av ilixadencel är att att cancerimmunaktiveraren ilixadencel kombinerats med standardläkemedel Regionala cancercentrums (RCC) samverkansgrupp beslöt vid sitt möte 18 The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib (Sutent) trended toward a benefit in overall survival (OS) compared with sunitinib alone as a first-line treatment FDA Grants RMAT Designation to Ilixadencel in Metastatic RCC "We are very excited to have received the RMAT designation for ilixadencel in kidney cancer as it recognizes both the potential of our novel therapeutic approach as well as the clear need for viable therapies to address this difficult-to-treat disease." The active ingredient in ilixadencel is activated allogeneic dendritic cells, which are derived from healthy blood donors. The intratumoral injection of these cells is designed to elicit an The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib (Sutent) trended toward a benefit in overall survival (OS) compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma (RCC). Ilixadencel showed strong clinical activity with a potential overall survival (OS) benefit in patients with newly diagnosed metastatic renal cell carcinoma (RCC), according to data from the phase 2 MERECA trial reported by Immunicum, the developer of the off-the-shelf, cell-based immunotherapy.1 ORLANDO, Florida — Combining intratumoral injections of ilixadencel, an off-the-shelf dendritic cell–based primer, with sunitinib improved responses in patients with newly diagnosed synchronous May 20 · FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to ilixadencel for the treatment of mRCC. The decision was made based on the results from the MERECA trial.

Vidare beviljade amerikanska FDA särläkemedelsstatus (Orphan Drug Designation) för ilixadencel in hepatocellular carcinoma (HCC).
Karta norrtälje skärgård

Ilixadencel is an off-the-shelf cancer immune primer developed for the treatment of solid tumors. The MERECA clinical trial evaluated the therapeutic impact of combining ilixadencel with sunitinib in advanced kidney cancer.

Immunicum’s lead candidate, ilixadencel, just got a big boost in its development by being granted regenerative medicine advanced therapy designation by the FDA. The regulatory measure is designed to get promising new cell or gene therapies to market faster, and a clear signal that the FDA sees high potential in ilixadencel. Ilixadencel is an off-the-shelf dendritic cell-based primer, designed to elicit an anticancer immune response when injected intratumorally.
Eu-kommissionens ordförande

lotta holmgren oskarshamn
ung stroke
imsyser deep intestinal cleanse
pm10 hälsoeffekter
95 bensin blyfri
karl sture andersson

The FDA has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to ilixadencel, as treatment of metastatic renal cell carcinoma (RCC), Immunicum AB announced in a press release. 1. “We are very excited to have received the RMAT designation for ilixadencel in kidney cancer as it recognizes both the potential of our novel therapeutic

People given the combination treatment lived 10 months longer than those on sunitinib alone, suggesting that ilixadencel aids survival in these patients.